171 related articles for article (PubMed ID: 28766363)
1. Future trends in outsourcing: a summary of the Bioanalysis Zone Survey.
Craddock A; Nadarajah S
Bioanalysis; 2017 Aug; 9(15):1127-1129. PubMed ID: 28766363
[No Abstract] [Full Text] [Related]
2. Outsourcing of bioanalysis at GSK: a hybrid approach with a robust support model.
Abberley L
Bioanalysis; 2017 Aug; 9(15):1139-1144. PubMed ID: 28762760
[No Abstract] [Full Text] [Related]
3. Bioanalytical outsourcing models in pharmaceutical companies.
Zimmer D
Bioanalysis; 2017 Aug; 9(15):1145-1148. PubMed ID: 28763250
[No Abstract] [Full Text] [Related]
4. Bioanalytical outsourcing: transitioning from Pharma to CRO.
Hayes R
Bioanalysis; 2017 Aug; 9(15):1149-1152. PubMed ID: 28763257
[No Abstract] [Full Text] [Related]
5. Bioanalytical outsourcing: the two sides of the medal.
Zimmer D
Bioanalysis; 2013 Sep; 5(17):2095-9. PubMed ID: 23962249
[No Abstract] [Full Text] [Related]
6. Outsourcing lead optimization: the eye of the storm.
Clark DE
Drug Discov Today; 2011 Feb; 16(3-4):147-57. PubMed ID: 21145413
[TBL] [Abstract][Full Text] [Related]
7. Changing shape: evolving an outsourced bioanalytical strategy to support the changing needs of drug development.
Stovold C; Milligan F; Hawthorne G; Pattison C; Wilson A
Bioanalysis; 2017 Aug; 9(15):1135-1137. PubMed ID: 28763237
[No Abstract] [Full Text] [Related]
8. Use of a collaborative tool to simplify the outsourcing of preclinical safety studies: an insight into the AstraZeneca-Charles River Laboratories strategic relationship.
Martin FDC; Benjamin A; MacLean R; Hollinshead DM; Landqvist C
Drug Discov Today; 2017 Dec; 22(12):1754-1759. PubMed ID: 28851537
[TBL] [Abstract][Full Text] [Related]
9. The quiet revolution: outsourcing in pharma.
Crossley R
Drug Discov Today; 2004 Aug; 9(16):694. PubMed ID: 15341780
[No Abstract] [Full Text] [Related]
10. Method transfer: a CRO perspective.
Hilhorst MJ; van der Strate BW; Briscoe CJ; van de Merbel NC
Bioanalysis; 2017 Aug; 9(15):1131-1134. PubMed ID: 28763238
[No Abstract] [Full Text] [Related]
11. Outsourcing is in.
Landhuis E
Nature; 2018 Apr; 556(7700):263-265. PubMed ID: 29643487
[No Abstract] [Full Text] [Related]
12. Biopharma CRO industry in China: landscape and opportunities.
Xia C; Gautam A
Drug Discov Today; 2015 Jul; 20(7):794-8. PubMed ID: 25701282
[TBL] [Abstract][Full Text] [Related]
13. Pharmaceutical futures: made in China?
Cyranoski D
Nature; 2008 Oct; 455(7217):1168-70. PubMed ID: 18971994
[No Abstract] [Full Text] [Related]
14. Outsourcing discovery.
Mallapaty S
Nature; 2017 Dec; 552(7683):S5. PubMed ID: 29219992
[No Abstract] [Full Text] [Related]
15. Outsourcing unit dose packaging.
Sanborn MD
Am J Health Syst Pharm; 2010 Jul; 67(13):1116-7. PubMed ID: 20554599
[No Abstract] [Full Text] [Related]
16. One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry.
Billette de Villemeur E; Versaevel B
J Health Econ; 2019 May; 65():260-283. PubMed ID: 31158785
[TBL] [Abstract][Full Text] [Related]
17. Biomanufacturing, from bust to boom...to bubble?
Thiel KA
Nat Biotechnol; 2004 Nov; 22(11):1365-72. PubMed ID: 15529157
[No Abstract] [Full Text] [Related]
18. Integrating internal and external bioanalytical support to deliver a diversified pharmaceutical portfolio.
Summerfield SG; Evans C; Spooner N; Dunn JA; Szapacs ME; Yang E
Bioanalysis; 2014 May; 6(10):1311-9. PubMed ID: 24958115
[TBL] [Abstract][Full Text] [Related]
19. A community of practice approach to bioanalysis delivery: the role of the Preclinical Bioanalysis and Toxicokinetics department at AstraZeneca.
Wilson A; Silvester S; Woods K
Bioanalysis; 2014 May; 6(10):1329-37. PubMed ID: 24958117
[TBL] [Abstract][Full Text] [Related]
20. AstraZeneca and Covance Laboratories Clinical Bioanalysis Alliance: an evolutionary outsourcing model.
Arfvidsson C; Severin P; Holmes V; Mitchell R; Bailey C; Cape S; Li Y; Harter T
Bioanalysis; 2017 Aug; 9(15):1181-1194. PubMed ID: 28762755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
